In support of the National Institute on Aging (NIA) and National Plan to Address Alzheimer’s Disease (NAPA), Daughters Against Alzheimer’s is honored to support the plan’s ambitious goals to both prevent future cases of Alzheimer’s and to meet the needs of the millions of American families currently facing these diseases. With their strong commitment to research, DAA is proud to support collaborative work among the world’s premier doctors, scientists, and researchers at Emory’s Goizueta Alzheimer’s Disease Research Center.
Battle for the Brain proceeds are donated to Emory’s Goizueta Alzheimer’s Disease Research Center and support unrestricted research relating to digital and traditional biomarkers so that we can detect and treat Alzheimer’s and dementia in their earliest stages.
2024 HAS BEEN AN EXCITING YEAR FOR RESEARCH AT DAUGHTERS AGAINST ALZHEIMER’S!
Now that the first generation of effective therapies for Alzheimer’s is finally here, our partners at Emory’s Goizueta Alzheimer’s Disease Research Center expect continued and rapid advances in the field.
With additional drugs targeting the clearance of amyloid pathology expected to receive FDA approval this year, we are getting closer to our eventual route to victory: the prevention of Alzheimer’s disease.
As research has shown that treatments for Alzheimer’s and dementia will be most effective if we can detect the different pathologies of the disease before cognitive problems occur, one of the keys to winning this battle lies in early detection.
Early diagnostics, specifically blood-based biomarker tests, will change the way we diagnose and treat Alzheimer’s and dementia, allowing us to detect problems early and prevent future cognitive decline.
“Just like LDL and HDL cholesterol testing has now become a part of routine medical care, we envision that laboratory testing for brain health with multiple different protein biomarkers will become a routine part of medical care. This will allow us to intervene early in the disease course and prevent cognitive decline later in life.” ~Erik C.B. Johnson, M.D., Ph.D., Goizueta Alzheimer's Disease Research Center.
